查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1692291

抗体药物偶联物市场 - 全球产业规模、份额、趋势、机会和预测，按类型、应用、地区和竞争细分，2020-2030 年

Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Types, By Application, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球抗体药物偶联物市场价值为 77.5 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 6.25%。抗体药物偶联物 (ADC) 市场是製药和生物技术产业内一个充满活力且快速发展的领域。 ADC 代表一类突破性的标靶癌症治疗方法，它结合了单株抗体 (mAb) 的特异性与细胞毒性药物的效力。这种协同作用能够将强效的抗癌剂直接精确地输送到癌细胞，同时保护健康组织，从而最大限度地减少与传统化疗相关的副作用。在多种关键因素的推动下，ADC 市场实现了大幅成长。首先，全球范围内以及各种癌症类型的癌症发生率不断上升，凸显了对创新有效治疗的迫切需求。 ADC 已成为一种有前景的解决方案，为治疗选择有限的患者提供更好的治疗效果。

市场概况
预测期 2026-2030
2024 年市场规模 77.5 亿美元
2030 年市场规模 110.6 亿美元
2025-2030 年复合年增长率 6.25％
成长最快的领域 单株抗体
最大的市场 北美洲

主要市场驱动因素

癌症发生率不断上升

主要市场挑战

肿瘤类型有限

主要市场趋势

针对各种癌症适应症的 ADC 候选药物不断增加。

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球抗体药物偶联物市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按类型（单株抗体、连接子、药物/毒素、其他）
    • 依应用（血癌、乳癌、卵巢癌、肺癌、脑瘤、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第 6 章：北美抗体药物偶联物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第 7 章：欧洲抗体药物偶联物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区抗体药物偶联物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲抗体药物偶联物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲抗体药物偶联物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章：全球抗体药物偶联物市场：SWOT 分析

第 14 章：竞争格局

  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Seattle Genetics Inc
  • Genentech Inc
  • Immunogen Inc
  • Immunomedics Inc
  • Progenics Pharmaceuticals Inc
  • Bayer HealthCare Pharmaceuticals Inc

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 18756

Global Antibody Drug Conjugates Market was valued at USD 7.75 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.25% through 2030. The Antibody Drug Conjugates (ADCs) Market is a dynamic and rapidly evolving segment within the pharmaceutical and biotechnology industries. ADCs represent a groundbreaking class of targeted cancer therapies that combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs. This synergy enables precise delivery of potent anticancer agents directly to cancer cells while sparing healthy tissue, thereby minimizing side effects associated with traditional chemotherapy. The market for ADCs has witnessed substantial growth driven by several key factors. Firstly, the increasing prevalence of cancer, both globally and across various cancer types, underscores the critical need for innovative and effective treatments. ADCs have emerged as a promising solution, offering improved therapeutic outcomes for patients with limited treatment options.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.75 Billion
Market Size 2030USD 11.06 Billion
CAGR 2025-20306.25%
Fastest Growing SegmentMonoclonal Antibodies
Largest MarketNorth America

Key Market Drivers

Growing prevalence of cancer

The growing prevalence of cancer serves as a compelling driver for the Global Antibody Drug Conjugates (ADCs) Market. Cancer has reached alarming proportions worldwide, with millions of new cases diagnosed annually. ADCs, a class of targeted cancer therapies, offer a ray of hope in the battle against this devastating disease. The rise in cancer cases underscores the unmet medical need for more effective and less toxic treatments. ADCs precisely deliver potent anticancer drugs to tumor cells, minimizing damage to healthy tissue, and hence are increasingly sought after. For instance, according to WHO, in 2022, an estimated 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally. By 2050, the cancer burden is expected to rise by 77%, placing greater pressure on health systems and communities. In the WHO Eastern Mediterranean Region, over 788,000 cancer cases were diagnosed in 2022. This number is projected to double to 1.57 million by 2045 due to population growth and widespread risk factors, including tobacco use, obesity, physical inactivity, unhealthy diets, and air pollution. Addressing these risks is crucial to mitigating the rising cancer burden in the region.

Key Market Challenges

Limited Tumor Types

Limited tumor types targeted by Antibody Drug Conjugates (ADCs) pose a significant challenge in the global market. ADCs are highly specific, and their effectiveness depends on the presence of specific antigens on cancer cells. This restricts their applicability to a select range of tumor types, leaving many cancers without effective ADC treatment options. Developing ADCs for a broader spectrum of tumors requires identifying suitable target antigens and investing in extensive research and development. Additionally, regulatory approval for new ADCs can be time-consuming and costly. Overcoming the limitation of tumor types is crucial to expand the market's reach and impact in the oncology field.

Key Market Trends

Growing pipeline of ADC candidates for various cancer indications.

The growing pipeline of Antibody Drug Conjugate (ADC) candidates for various cancer indications is a noteworthy trend in the global ADC market. This trend reflects the increasing interest and investment in ADC research and development, driven by several factors: The ADC field has witnessed a surge in research and investment, leading to the development of a diverse range of ADC candidates. These candidates target various cancer indications, including solid tumors and hematological malignancies. This expansion of the therapeutic landscape is a response to the unmet medical needs across different cancer types. ADCs are known for their precision in targeting cancer cells while sparing healthy tissues. Advancements in genomics and biomarker discovery have enabled the identification of specific antigens and genetic profiles associated with different cancer types. This knowledge allows for the design of ADCs tailored to individual cancer subtypes, promoting personalized treatment approaches. The development of ADCs often goes hand in hand with research into combination therapies. Combining ADCs with other targeted therapies, immunotherapies, or standard chemotherapy regimens can enhance treatment efficacy. This trend aligns with the growing interest in combination approaches to address complex cancer biology. As cancer cells can develop resistance to single-agent therapies, researchers are exploring ADCs as a strategy to overcome resistance mechanisms. This has led to the development of ADCs that target specific resistance pathways or employ alternative mechanisms of action.

Key Market Players

  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Seattle Genetics Inc
  • Genentech Inc
  • Immunogen Inc
  • Immunomedics Inc
  • Progenics Pharmaceuticals Inc
  • Bayer HealthCare Pharmaceuticals Inc

Report Scope:

In this report, the Global Antibody Drug Conjugates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antibody Drug Conjugates Market, By Type:

  • Monoclonal Antibodies
  • Linker
  • Drug/Toxin
  • Others

Antibody Drug Conjugates Market, By Application:

  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor
  • Others

Antibody Drug Conjugates Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Antibody Drug Conjugates Market.

Available Customizations:

Global Antibody Drug Conjugates market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antibody Drug Conjugates Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Types (Monoclonal Antibodies, Linker, Drug/Toxin, Others)
    • 5.2.2. By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Antibody Drug Conjugates Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Types
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antibody Drug Conjugates Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Types
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Antibody Drug Conjugates Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Types
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Antibody Drug Conjugates Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Types
        • 6.3.3.2.2. By Application

7. Europe Antibody Drug Conjugates Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Types
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antibody Drug Conjugates Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Types
        • 7.3.1.2.2. By Application
    • 7.3.2. United Kingdom Antibody Drug Conjugates Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Types
        • 7.3.2.2.2. By Application
    • 7.3.3. Italy Antibody Drug Conjugates Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Types
        • 7.3.3.2.2. By Application
    • 7.3.4. France Antibody Drug Conjugates Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Types
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Antibody Drug Conjugates Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Types
        • 7.3.5.2.2. By Application

8. Asia-Pacific Antibody Drug Conjugates Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Types
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Antibody Drug Conjugates Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Types
        • 8.3.1.2.2. By Application
    • 8.3.2. India Antibody Drug Conjugates Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Types
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Antibody Drug Conjugates Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Types
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Antibody Drug Conjugates Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Types
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Antibody Drug Conjugates Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Types
        • 8.3.5.2.2. By Application

9. South America Antibody Drug Conjugates Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Types
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Antibody Drug Conjugates Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Types
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Antibody Drug Conjugates Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Types
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Antibody Drug Conjugates Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Types
        • 9.3.3.2.2. By Application

10. Middle East and Africa Antibody Drug Conjugates Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Types
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Antibody Drug Conjugates Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Types
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Antibody Drug Conjugates Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Types
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Antibody Drug Conjugates Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Types
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisition

13. Global Antibody Drug Conjugates Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Novartis AG
    • 14.1.1. Business Overview
    • 14.1.2. Treatment Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Key Personnel
    • 14.1.5. SWOT Analysis
  • 14.2. F. Hoffmann-La Roche Ltd
  • 14.3. Takeda Pharmaceutical Company Limited
  • 14.4. Pfizer Inc.
  • 14.5. Seattle Genetics Inc
  • 14.6. Genentech Inc
  • 14.7. Immunogen Inc
  • 14.8. Immunomedics Inc
  • 14.9. Progenics Pharmaceuticals Inc
  • 14.10.Bayer HealthCare Pharmaceuticals Inc

15. Strategic Recommendations

16. About Us & Disclaimer